Mark Emalfarb

“Joe described how commercial products are helping validate our platforms across life sciences, food and nutrition, and bioindustrial markets. Our biopharmaceutical programs are doing something similar at the more regulated end of the protein spectrum.”

“While Dyadic's primary commercial focus remains on non-pharmaceutical markets, our biopharmaceutical activities continue to play an important strategic role by validating the capabilities of the C1 platform, generating non-dilutive funding, and creating potential potential future licensing and partnership…”

“We continue to advance our partner-funded biopharmaceutical collaborations, applying a C1 platform into vaccines and antibody development to a non-dilutive capital efficient model.”

“Our biopharmaceutical programs are accelerating and delivering meaningful advancements in vaccine and therapeutic protein development for both animal and human health.”

“I'm not quite sure what you mean by conflict, but we don't see any...”